Nvidia (NASDAQ: NVDA) has been a great stock to own, and it could remain that way for long-term investors. However, the problem is that it's trading at nearly 40 times its future profits. At such a high valuation, it sets a high bar for the business and effectively prices in a lot of future growth already. ...
motleyfoolusx:abbvusx:nvda
Relax, do what you enjoy, and rake in money. That probably sounds like a great life for most people. Making it a reality isn't easy, but it's possible. The key is to generate passive income. You'll need to have money to make money, but once you've got it, there are plenty of great alternatives to put ...
motleyfoolusx:abbv
When it comes to investing, I often look for companies that generate strong amounts of free cash flow (FCF), and companies that can grow their FCF. One company that has proven that over the years is AbbVie (NYSE: ABBV). I often refer to it as The Investor's Trifecta, offering growth potential, high yield, ...
motleyfoolusx:abbv
There are plenty of reasons to buy a leading biopharma business like AbbVie (NYSE: ABBV), and investors just got at least a few more. Thanks to a large acquisition that came out of left field, it could now become a prominent psychiatric-drug company. Though the area isn't traditionally in AbbVie's wheelhouse, ...
motleyfoolusx:abbv
Wall Street is feeling pretty good about AbbVie's (NYSE: ABBV) performance in 2024 so far. Louise Chen from Cantor Fitzgerald recently initiated coverage on the stock with an overweight rating. Chen also slapped a $200 price target on the pharma stock, which implies a gain of more than 20% from recent ...
motleyfoolusx:abbv
Many investors hold a stake in AbbVie (NYSE: ABBV) because it offers exposure to the healthcare sector. Industry-based diversification, however, isn't all the pharmaceutical outfit brings to the table. AbbVie is also a quality dividend stock. If you're looking for a name that serves such a dual purpose, ...
motleyfoolusx:abbv
When it comes to dividend investing, I am constantly looking for high-quality companies with strong free cash flows that pay safe, reliable, and growing dividends. In today's video, I will show you how you can earn $1000 every month in dividend income from a simple three-stock portfolio. One of those ...
motleyfoolusx:abbv
The healthcare industry is a fantastic place to find passive income. Healthcare is recession-proof, and there's always a need for better technology and new treatments. The industry's top dogs have been in the game for decades and can generate wealth for patient shareholders who come along for the ride. ...
motleyfoolusx:abbvusx:llyusx:nvo
Dividend stocks can be great assets for you in retirement. They can provide you with some recurring income, and they can be relatively safe places to invest your money into for a while. Not all high-yielding stocks are safe, but by going with established, top companies within their respective industries, ...
motleyfoolusx:xomusx:tusx:abbv
It's been more than a year since AbbVie (NYSE: ABBV) lost patent exclusivity for its most important product, Humira, an immunology medicine. Though this was a long time coming, the market reacted as though it was unexpected: AbbVie's shares dropped once the magnitude of Humira's sales decline became ...
motleyfoolusx:abbv
By almost any measure, AbbVie (NYSE: ABBV) shares should have risen Friday. The pharmaceutical giant delivered first-quarter sales and earnings results that topped estimates. The decline in sales of multi-indication immunosuppressive drug Humira -- a natural result of its loss of patent exclusivity -- ...
motleyfoolusx:abbv
Image source: The Motley Fool. AbbVie (NYSE: ABBV) Q1 2024 Earnings Call Apr 26, 2024, 9:00 a.m. ET Operator Continue reading
motleyfoolusx:abbv
Specialty biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) Friday announced first-quarter 2024 financial results, reporting a decline in adjusted earnings and a modest rise in revenues. The company reported worldwide net revenues of $12.31 billion for the March quarter, up 1% from the corresponding ...
alphastreetusx:abbv
We have seen a stock pullback here in April, and three of these high-quality dividend paying stocks look quite intriguing. One of those stocks is healthcare company AbbVie (NYSE: ABBV) which I consider to be an Investor's Trifecta, offering growth potential, high yield, and dividend growth. Check out ...
motleyfoolusx:abbv
Having largely covered every valuable dividend stock in the UK market, I decided to see what’s happening across the pond. US stocks on average don’t appear to pay as high dividends as the UK, with a stronger focus on growth. However, I’ve uncovered three US stocks that could secure investors decent value ...
motleyfoolukusx:abbvusx:ibmusx:vz
Big pharma stocks like AbbVie (NYSE: ABBV) usually aren't high on the list that investors look to for opportunities that could make them into millionaires. After all, they aren't typically in the news for good reasons, and despite relying on the lifesaving medicines that they produce, most people aren't ...
motleyfoolusx:abbv
